
Shires Income PLC 31
Strategic Report Governance Overview General Portfolio Corporate Information Financial Statements
There was only one meaningful trade in September,
switching UK housebuilder Berkeley Group into peer
Barratt. The move came ahead of Barratt going ex-
dividend, so we captured some additional income, but the
investment primarily reflected the fact that Barratt had
lagged the sector following its deal to buy Redrow.
The remaining holding in GSK was sold in October. This is
our least preferred large-cap pharma company and,
while the recent Zantac litigation progress has been
positive, this has been offset by some uncertainty on
vaccine sales rates.
In November, one new holding was added, French listed
Gaztransport Et Technigaz (“GTT”), with the position
funded by selling TotalEnergies to maintain the weight to
energy. GTT provides the membrane containment
technology to liquefied natural gas (“LNG”) carriers, which
ship cooled gas between international markets. This is a
growing market as LNG import and export capacity
expands. The market will require greater tanker capacity
and GTT dominates this space with high technological
barriers to entry. It has a strong order book, and we expect
that, as the tanker fleet ages in the next few years, we will
see a growing replacement market, supporting long term
cashflows. The company has a strong balance sheet,
provides a high return on capital and pays a high dividend
yield. This switch also reduces commodity price leverage
in the portfolio. Given a mixed outlook for energy demand
in 2025, we don’t think that is a bad thing.
In December the weight in Standard Chartered was
reduced, with the capital used to buy back into ING. ING
was only sold in August, but Standard Chartered
outperformed it by 30% in the four months since, and with
a defensive mix and high yield it looked attractive. The
other notable trade in the month was to exit animal
genetics provider Genus. While Genus remains a high-
quality business with high barriers to entry,
underperformance meant it had fallen below our
minimum position size, forcing the question of “up or out”.
With risks to the timing of its disease resistant genetics and
low yield we chose to move on.
At the start of January, we started a new position in UK
bank Barclays. The position was funded by selling down
some of the holding in NatWest which had performed very
well. The move helped to diversify the exposure to UK
banks and to increase exposure to capital markets where
we saw more potential for positive surprise in 2025. During
January we also switched the position in Aviva preference
shares into the equity. The preference shares deliver a
reliable, high yield, but equities generally have better long-
term growth prospects. In the case of Aviva, the equity
also offered a premium yield to the preference shares and
there is an opportunity for the company to extract
meaningful synergies from the recent acquisition of Direct
Line, resulting in some earnings upgrades. That makes the
equity relatively more attractive. The position in Italian
utility Enel was also sold during the month. The share had
risen by approximately 30% since the addition to the
portfolio in mid-2023 and we had become less attracted
to the company.
During February there were changes to the UK consumer
discretionary exposure, with the holding in Dr. Martens sold
and the proceeds reinvested into Dunelm. Although we see
good long-term potential from Dr. Martens under new
management, the share price had rallied and the shares
do not deliver a meaningful income. By contrast, Dunelm
had de-rated due to concerns around the UK consumer
and remains a high quality, cash generative, retailer. With
a special dividend coming up and a business model that
continues to win market share through the cycle, we saw it
as a better balance of risk and reward in the current
environment. The exposure to UK housebuilders was also
changed in February, switching from Barratt Redrow into
Taylor Wimpey. The change reflected a materially higher
dividend yield from Taylor Wimpey, making it a more
attractive way to gain exposure to market improvement
for the portfolio. Finally, we also switched holdings in
European banks during the month, selling ING and buying
Italian bank Intesa Sanpaolo. Intesa Sanpaolo has a higher
dividend yield and its weighting to investment services
offers stronger long term growth and better protection for
income if interest rates move lower in Europe.
Closing the year, March was an active month for trading.
At the start of the month, we sold out of the remaining
position in 4Imprint, reflecting potential headwinds from
higher tariffs and slower economic activity in the US. We
like the company, but saw it as fairly priced at those levels,
with the dividend yield only marginally above the
benchmark level. We also started a new position in self-
storage provider Safestore. The shares have been very
weak recently and now offer a yield of over 5%. The
shares are trading at a material discount to asset value,
providing downside protection. We also sold out of the
remaining position in Novo-Nordisk. This has been a great
holding over recent years but has moved down our order
of preference in the healthcare sector as competition has
increased and it offers limited yield.